{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T02:39:00Z","timestamp":1791859140527,"version":"4.3.4"},"reference-count":56,"publisher":"Oxford University Press (OUP)","issue":"1","license":[{"start":{"date-parts":[[2025,12,12]],"date-time":"2025-12-12T00:00:00Z","timestamp":1765497600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100010659","name":"Erasmus MC","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100010659","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,1,6]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Introduction<\/jats:title>\n                    <jats:p>\u03b2-Lactam antibiotics are among the most frequently prescribed antibiotics on the paediatric ICU (PICU). For \u03b2-lactam antibiotics, unbound plasma concentrations above at least one to four times the MIC for 100% of the dosing interval (100% \u0192T\u200a&amp;gt;\u200a1\u20134\u00d7MIC) have been proposed as the pharmacodynamic target. This study aimed to determine target attainment of \u03b2-lactam antibiotics in PICUs and to identify predictors of target non-attainment.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Patients and methods<\/jats:title>\n                    <jats:p>This prospective observational study was performed in two PICUs in the Netherlands. We enrolled paediatric patients treated with the following \u03b2-lactam antibiotics: cefotaxime, ceftazidime, ceftriaxone, cefuroxime, flucloxacillin and meropenem. The free concentration above the bacterial epidemiological cut-off minimum inhibitory concentration (\u0192T\u200a&amp;gt;\u200aMICECOFF and \u0192T\u200a&amp;gt;\u200a4\u00d7MICECOFF) was determined. Secondary endpoints were estimated regression models for examining the association of target non-attainment with patient characteristics and clinical outcomes.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>A total of 116 patients were included, of whom 27.6% achieved 100% \u0192T\u200a&amp;gt;\u200aMICECOFF and 13.7% achieved 100% \u0192T\u200a&amp;gt;\u200a4\u00d7MICECOFF. Regression analysis identified an estimated glomerular filtration rate (eGFR) \u226590\u2005mL\/min\/1.73\u200am2 as a risk factor for target non-attainment. In addition, no significant association between the 100% \u0192T\u200a&amp;gt;\u200aMICECOFF target attainment and ICU length of stay (LOS) was found. However, for both pharmacodynamic targets, a significant correlation was found between LOS and age in years.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>This study found an eGFR \u226590\u2005mL\/min\/1.73\u200am2 to be associated with target non-attainment, indicating that kidney function should be taken into account when identifying individuals who may require higher dosages. These results may help identify subpopulations of paediatric patients requiring higher dosages or continuous infusion in order to achieve adequate \u03b2-lactam exposure.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/jac\/dkaf457","type":"journal-article","created":{"date-parts":[[2025,12,9]],"date-time":"2025-12-09T13:07:14Z","timestamp":1765285634000},"source":"Crossref","is-referenced-by-count":5,"title":["\u03b2-Lactam dosing in critically ill children: predictors for target non-attainment"],"prefix":"10.1093","volume":"81","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1835-0749","authenticated-orcid":false,"given":"Stef","family":"Schouwenburg","sequence":"first","affiliation":[{"name":"Department of Hospital Pharmacy, Erasmus University Medical Centre , Rotterdam ,","place":["The Netherlands"]},{"name":"Rotterdam Clinical Pharmacometrics Group, Erasmus University Medical Centre , Rotterdam ,","place":["The Netherlands"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6953-0358","authenticated-orcid":false,"given":"Tim","family":"Preijers","sequence":"additional","affiliation":[{"name":"Department of Hospital Pharmacy, Erasmus University Medical Centre , Rotterdam ,","place":["The Netherlands"]},{"name":"Rotterdam Clinical Pharmacometrics Group, Erasmus University Medical Centre , Rotterdam ,","place":["The Netherlands"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roelie M","family":"W\u00f6sten-Van Asperen","sequence":"additional","affiliation":[{"name":"Department of Pediatric Intensive Care, University Medical Center Utrecht\/Wilhelmina Children\u2019s Hospital , Utrecht ,","place":["The Netherlands"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0005-5197-2656","authenticated-orcid":false,"given":"Enno D","family":"Wildschut","sequence":"additional","affiliation":[{"name":"Department of Neonatal and Pediatric Intensive Care, Division of Neonatology, Erasmus University Medical Centre-Sophia Children\u2019s Hospital , Rotterdam ,","place":["The Netherlands"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nelianne J","family":"Verkaik","sequence":"additional","affiliation":[{"name":"Department of Medical Microbiology and Infectious Diseases, Erasmus University Medical Center , Rotterdam ,","place":["The Netherlands"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2158-6376","authenticated-orcid":false,"given":"Alan","family":"Abdulla","sequence":"additional","affiliation":[{"name":"Rotterdam Clinical Pharmacometrics Group, Erasmus University Medical Centre , Rotterdam ,","place":["The Netherlands"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthijs","family":"de Hoog","sequence":"additional","affiliation":[{"name":"Department of Neonatal and Pediatric Intensive Care, Division of Neonatology, Erasmus University Medical Centre-Sophia Children\u2019s Hospital , Rotterdam ,","place":["The Netherlands"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1202-3643","authenticated-orcid":false,"given":"Birgit C P","family":"Koch","sequence":"additional","affiliation":[{"name":"Department of Hospital Pharmacy, Erasmus University Medical Centre , Rotterdam ,","place":["The Netherlands"]},{"name":"Rotterdam Clinical Pharmacometrics Group, Erasmus University Medical Centre , Rotterdam ,","place":["The Netherlands"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2025,12,12]]},"reference":[{"key":"2026011413271342000_dkaf457-B1","doi-asserted-by":"publisher","first-page":"e52","DOI":"10.1097\/PCC.0000000000002198","article-title":"Surviving sepsis campaign international guidelines for the management of septic shock and sepsis-associated organ dysfunction in children","volume":"21","author":"Weiss","year":"2020","journal-title":"Pediatr Crit Care Med"},{"key":"2026011413271342000_dkaf457-B2","doi-asserted-by":"publisher","first-page":"1182","DOI":"10.3390\/antibiotics10101182","article-title":"Pharmacokinetics of antibiotics in pediatric intensive care: fostering variability to attain precision medicine","volume":"10","author":"Gijsen","year":"2021","journal-title":"Antibiotics (Basel)"},{"key":"2026011413271342000_dkaf457-B3","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1007\/s11095-016-2033-y","article-title":"Clinical pharmacology studies in critically ill children","volume":"34","author":"Thakkar","year":"2017","journal-title":"Pharm Res"},{"key":"2026011413271342000_dkaf457-B4","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1007\/s00467-018-4120-2","article-title":"Augmented renal clearance in pediatric intensive care: are we undertreating our sickest patients?","volume":"35","author":"Dhont","year":"2020","journal-title":"Pediatr Nephrol"},{"key":"2026011413271342000_dkaf457-B5","doi-asserted-by":"publisher","first-page":"777","DOI":"10.1111\/bcp.13160","article-title":"Scaling clearance in paediatric pharmacokinetics: all models are wrong, which are useful?","volume":"83","author":"Germovsek","year":"2017","journal-title":"Br J Clin Pharmacol"},{"key":"2026011413271342000_dkaf457-B6","doi-asserted-by":"publisher","first-page":"777854","DOI":"10.3389\/fped.2022.777854","article-title":"Beta-lactams therapeutic monitoring in septic children\u2014what target are we aiming for? A scoping review","volume":"10","author":"Morales Junior","year":"2022","journal-title":"Front Pediatr"},{"key":"2026011413271342000_dkaf457-B7","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1086\/516284","article-title":"Pharmacokinetic\/pharmacodynamic parameters: rationale for antibacterial dosing of mice and men","volume":"26","author":"Craig","year":"1998","journal-title":"Clin Infect Dis"},{"key":"2026011413271342000_dkaf457-B8","doi-asserted-by":"publisher","first-page":"1044683","DOI":"10.3389\/fphar.2022.1044683","article-title":"\u03b2-Lactam precision dosing in critically ill children: current state and knowledge gaps","volume":"13","author":"Tang Girdwood","year":"2022","journal-title":"Front Pharmacol"},{"key":"2026011413271342000_dkaf457-B9","doi-asserted-by":"publisher","first-page":"425","DOI":"10.1093\/jac\/dkf130","article-title":"Pharmacodynamics of cefepime in patients with Gram-negative infections","volume":"50","author":"Tam","year":"2002","journal-title":"J Antimicrob Chemother"},{"key":"2026011413271342000_dkaf457-B10","doi-asserted-by":"publisher","first-page":"345","DOI":"10.1016\/j.ijantimicag.2007.12.009","article-title":"Evaluation of area under the inhibitory curve (AUIC) and time above the minimum inhibitory concentration (T\u200a&gt;\u200aMIC) as predictors of outcome for cefepime and ceftazidime in serious bacterial infections","volume":"31","author":"McKinnon","year":"2008","journal-title":"Int J Antimicrob Agents"},{"key":"2026011413271342000_dkaf457-B11","doi-asserted-by":"publisher","first-page":"840","DOI":"10.1097\/CCM.0b013e3181961bff","article-title":"Pharmacokinetic issues for antibiotics in the critically ill patient","volume":"37","author":"Roberts","year":"2009","journal-title":"Crit Care Med"},{"key":"2026011413271342000_dkaf457-B12","doi-asserted-by":"publisher","first-page":"903","DOI":"10.2165\/11595960-000000000-00000","article-title":"Pharmacokinetics and pharmacodynamics of meropenem in elderly Chinese with lower respiratory tract infections: population pharmacokinetics analysis using nonlinear mixed-effects modelling and clinical pharmacodynamics study","volume":"28","author":"Zhou","year":"2011","journal-title":"Drugs Aging"},{"key":"2026011413271342000_dkaf457-B13","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1016\/j.ijantimicag.2011.10.011","article-title":"Continuous infusion of piperacillin\/tazobactam in ventilator-associated pneumonia: a pilot study on efficacy and costs","volume":"39","author":"Duszynska","year":"2012","journal-title":"Int J Antimicrob Agents"},{"key":"2026011413271342000_dkaf457-B14","doi-asserted-by":"publisher","first-page":"e0446","DOI":"10.1097\/CCE.0000000000000446","article-title":"Setting the beta-lactam therapeutic range for critically ill patients: is there a floor or even a ceiling?","volume":"3","author":"Barreto","year":"2021","journal-title":"Crit Care Explor"},{"key":"2026011413271342000_dkaf457-B15","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1186\/s13054-019-2378-9","article-title":"Optimization of the treatment with beta-lactam antibiotics in critically ill patients\u2014guidelines from the French Society of Pharmacology and Therapeutics (Soci\u00e9t\u00e9 Fran\u00e7aise de Pharmacologie et Th\u00e9rapeutique-SFPT) and the French Society of Anaesthesia and Intensive Care Medicine (Soci\u00e9t\u00e9 Fran\u00e7aise d'Anesth\u00e9sie et R\u00e9animation-SFAR)","volume":"23","author":"Guilhaumou","year":"2019","journal-title":"Crit Care"},{"key":"2026011413271342000_dkaf457-B16","doi-asserted-by":"publisher","first-page":"272","DOI":"10.1097\/CCM.0000000000002817","article-title":"\u03b2-Lactam therapeutic drug management in the PICU","volume":"46","author":"Cies","year":"2018","journal-title":"Crit Care Med"},{"key":"2026011413271342000_dkaf457-B17","doi-asserted-by":"publisher","first-page":"2891","DOI":"10.1093\/jac\/dkx209","article-title":"Too much of a good thing: a retrospective study of \u03b2-lactam concentration-toxicity relationships","volume":"72","author":"Imani","year":"2017","journal-title":"J Antimicrob Chemother"},{"key":"2026011413271342000_dkaf457-B18","doi-asserted-by":"publisher","first-page":"1760","DOI":"10.1007\/s00134-022-06921-9","article-title":"Model-informed precision dosing of beta-lactam antibiotics and ciprofloxacin in critically ill patients: a multicentre randomised clinical trial","volume":"48","author":"Ewoldt","year":"2022","journal-title":"Intensive Care Med"},{"key":"2026011413271342000_dkaf457-B19","doi-asserted-by":"publisher","first-page":"845","DOI":"10.1016\/j.cmi.2023.03.018","article-title":"Individualized antimicrobial dose optimization: a systematic review and meta-analysis of randomized controlled trials","volume":"29","author":"Sanz-Codina","year":"2023","journal-title":"Clin Microbiol Infect"},{"key":"2026011413271342000_dkaf457-B20","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1007\/s40262-019-00813-w","article-title":"Pharmacokinetics and target attainment of antibiotics in critically ill children: a systematic review of current literature","volume":"59","author":"Hartman","year":"2020","journal-title":"Clin Pharmacokinet"},{"key":"2026011413271342000_dkaf457-B21","doi-asserted-by":"publisher","first-page":"750080","DOI":"10.3389\/fphar.2021.750080","article-title":"The pharmacokinetics of beta-lactam antibiotics using scavenged samples in pediatric intensive care patients: the EXPAT kids study protocol","volume":"12","author":"Schouwenburg","year":"2021","journal-title":"Front Pharmacol"},{"key":"2026011413271342000_dkaf457-B22","doi-asserted-by":"publisher","first-page":"138","DOI":"10.1016\/j.jchromb.2017.06.014","article-title":"Simultaneous determination of nine \u03b2-lactam antibiotics in human plasma by an ultrafast hydrophilic-interaction chromatography\u2013tandem mass spectrometry","volume":"1060","author":"Abdulla","year":"2017","journal-title":"J Chromatogr B Analyt Technol Biomed Life Sci"},{"key":"2026011413271342000_dkaf457-B23","author":"EUCAST"},{"key":"2026011413271342000_dkaf457-B24","doi-asserted-by":"publisher","first-page":"897","DOI":"10.1016\/S0140-6736(06)68371-2","article-title":"Paediatric logistic organ dysfunction (PELOD) score","volume":"367","author":"Leteurtre","year":"2006","journal-title":"Lancet"},{"key":"2026011413271342000_dkaf457-B25","doi-asserted-by":"publisher","first-page":"629","DOI":"10.1681\/ASN.2008030287","article-title":"New equations to estimate GFR in children with CKD","volume":"20","author":"Schwartz","year":"2009","journal-title":"J Am Soc Nephrol"},{"key":"2026011413271342000_dkaf457-B26","doi-asserted-by":"publisher","first-page":"99","DOI":"10.2165\/11539220-000000000-00000","article-title":"The effects of hypoalbuminaemia on optimizing antibacterial dosing in critically ill patients","volume":"50","author":"Ulldemolins","year":"2011","journal-title":"Clin Pharmacokinet"},{"key":"2026011413271342000_dkaf457-B27","doi-asserted-by":"publisher","first-page":"900551","DOI":"10.3389\/fphar.2022.900551","article-title":"An overview of the protein binding of cephalosporins in human body fluids: a systematic review","volume":"13","author":"Jongmans","year":"2022","journal-title":"Front Pharmacol"},{"key":"2026011413271342000_dkaf457-B28","doi-asserted-by":"publisher","first-page":"30","DOI":"10.3978\/j.issn.2305-5839.2015.12.63","article-title":"Multiple imputation with multivariate imputation by chained equation (MICE) package","volume":"4","author":"Zhang","year":"2016","journal-title":"Ann Transl Med"},{"key":"2026011413271342000_dkaf457-B29","doi-asserted-by":"publisher","first-page":"332","DOI":"10.1016\/j.ijantimicag.2010.06.008","article-title":"Therapeutic drug monitoring of beta-lactams in critically ill patients: proof of concept","volume":"36","author":"Roberts","year":"2010","journal-title":"Int J Antimicrob Agents"},{"key":"2026011413271342000_dkaf457-B30","doi-asserted-by":"publisher","first-page":"871","DOI":"10.1164\/rccm.202310-1926OC","article-title":"Association between age and mortality in pediatric and adult acute respiratory distress syndrome","volume":"209","author":"Patel","year":"2024","journal-title":"Am J Respir Crit Care Med"},{"key":"2026011413271342000_dkaf457-B31","doi-asserted-by":"publisher","first-page":"R35","DOI":"10.1186\/cc12544","article-title":"Augmented renal clearance in septic and traumatized patients with normal plasma creatinine concentrations: identifying at-risk patients","volume":"17","author":"Udy","year":"2013","journal-title":"Crit Care"},{"key":"2026011413271342000_dkaf457-B32","doi-asserted-by":"publisher","first-page":"1099","DOI":"10.1007\/s00467-019-04205-x","article-title":"Augmented renal clearance: a common condition in critically ill children","volume":"34","author":"Van Der Heggen","year":"2019","journal-title":"Pediatr Nephrol"},{"key":"2026011413271342000_dkaf457-B33","doi-asserted-by":"publisher","first-page":"1607","DOI":"10.1007\/s00467-023-06221-4","article-title":"Predictors of augmented renal clearance based on iohexol plasma clearance in critically ill children","volume":"39","author":"Dhont","year":"2024","journal-title":"Pediatr Nephrol"},{"key":"2026011413271342000_dkaf457-B34","doi-asserted-by":"publisher","first-page":"e309","DOI":"10.1097\/PCC.0000000000002951","article-title":"Suboptimal beta-lactam therapy in critically ill children: risk factors and outcome","volume":"23","author":"Van Der Heggen","year":"2022","journal-title":"Pediatr Crit Care Med"},{"key":"2026011413271342000_dkaf457-B35","doi-asserted-by":"publisher","first-page":"385","DOI":"10.1016\/j.ijantimicag.2014.12.017","article-title":"Augmented renal clearance, low \u03b2-lactam concentrations and clinical outcomes in the critically ill: an observational prospective cohort study","volume":"45","author":"Huttner","year":"2015","journal-title":"Int J Antimicrob Agents"},{"key":"2026011413271342000_dkaf457-B36","doi-asserted-by":"publisher","first-page":"1255","DOI":"10.1007\/s10096-019-03535-w","article-title":"Target attainment of cefotaxime in critically ill children with meningococcal septic shock as a model for cefotaxime dosing in severe pediatric sepsis","volume":"38","author":"Hartman","year":"2019","journal-title":"Eur J Clin Microbiol Infect Dis"},{"key":"2026011413271342000_dkaf457-B37","doi-asserted-by":"publisher","first-page":"1361","DOI":"10.1007\/s40262-021-01035-9","article-title":"Current ceftriaxone dose recommendations are adequate for most critically ill children: results of a population pharmacokinetic modeling and simulation study","volume":"60","author":"Hartman","year":"2021","journal-title":"Clin Pharmacokinet"},{"key":"2026011413271342000_dkaf457-B38","doi-asserted-by":"publisher","first-page":"585","DOI":"10.1007\/s40262-025-01486-4","article-title":"Leveraging clinical data to enhance the performance evaluation of ceftriaxone population pharmacokinetic models in children","volume":"64","author":"Schouwenburg","year":"2025","journal-title":"Clin Pharmacokinet"},{"key":"2026011413271342000_dkaf457-B39","doi-asserted-by":"publisher","first-page":"e17831","DOI":"10.7759\/cureus.17831","article-title":"Cefepime-induced neurotoxicity","volume":"13","author":"Saini","year":"2021","journal-title":"Cureus"},{"key":"2026011413271342000_dkaf457-B40","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1016\/j.ijid.2022.01.023","article-title":"Ceftriaxone-associated encephalopathy in a patient with high levels of ceftriaxone in blood and cerebrospinal fluid","volume":"116","author":"Nishioka","year":"2022","journal-title":"Int J Infect Dis"},{"key":"2026011413271342000_dkaf457-B41","doi-asserted-by":"publisher","first-page":"740","DOI":"10.1002\/phar.2842","article-title":"International consensus recommendations for the use of prolonged-infusion beta-lactam antibiotics: endorsed by the American College of Clinical Pharmacy, British Society for Antimicrobial Chemotherapy, Cystic Fibrosis Foundation, European Society of Clinical Microbiology and Infectious Diseases, Infectious Diseases Society of America, Society of Critical Care Medicine, and Society of Infectious Diseases Pharmacists","volume":"43","author":"Hong","year":"2023","journal-title":"Pharmacotherapy"},{"key":"2026011413271342000_dkaf457-B42","doi-asserted-by":"publisher","first-page":"564","DOI":"10.1093\/jac\/dkx427","article-title":"MIC-based dose adjustment: facts and fables","volume":"73","author":"Mouton","year":"2018","journal-title":"J Antimicrob Chemother"},{"key":"2026011413271342000_dkaf457-B43","doi-asserted-by":"publisher","first-page":"379","DOI":"10.1186\/s13054-019-2621-4","article-title":"Increased \u03b2-lactams dosing regimens improve clinical outcome in critically ill patients with augmented renal clearance treated for a first episode of hospital or ventilator-acquired pneumonia: a before and after study","volume":"23","author":"Carri\u00e9","year":"2019","journal-title":"Crit Care"},{"key":"2026011413271342000_dkaf457-B44","doi-asserted-by":"publisher","first-page":"2171","DOI":"10.1007\/s10096-018-3357-9","article-title":"An evaluation of risk factors to predict target concentration non-attainment in critically ill patients prior to empiric \u03b2-lactam therapy","volume":"37","author":"Imani","year":"2018","journal-title":"Eur J Clin Microbiol Infect Dis"},{"key":"2026011413271342000_dkaf457-B45","doi-asserted-by":"publisher","first-page":"1078","DOI":"10.1093\/jac\/dky553","article-title":"Tolerability of high-dose ceftriaxone in CNS infections: a prospective multicentre cohort study","volume":"74","author":"Le Turnier","year":"2019","journal-title":"J Antimicrob Chemother"},{"key":"2026011413271342000_dkaf457-B46","doi-asserted-by":"publisher","first-page":"198","DOI":"10.5863\/1551-6776-25.3.198","article-title":"Continuous infusion vancomycin in pediatric patients: a critical review of the evidence","volume":"25","author":"Girand","year":"2020","journal-title":"J Pediatr Pharmacol Ther"},{"key":"2026011413271342000_dkaf457-B47","doi-asserted-by":"publisher","first-page":"629","DOI":"10.1001\/jama.2024.9779","article-title":"Continuous vs intermittent \u03b2-lactam antibiotic infusions in critically ill patients with sepsis: the BLING III randomized clinical trial","volume":"332","author":"Dulhunty","year":"2024","journal-title":"JAMA"},{"key":"2026011413271342000_dkaf457-B48","doi-asserted-by":"publisher","first-page":"214","DOI":"10.5863\/1551-6776-27.3.214","article-title":"A review of extended and continuous infusion beta-lactams in pediatric patients","volume":"27","author":"Imburgia","year":"2022","journal-title":"J Pediatr Pharmacol Ther"},{"key":"2026011413271342000_dkaf457-B49","doi-asserted-by":"publisher","first-page":"638","DOI":"10.1001\/jama.2024.9803","article-title":"Prolonged vs intermittent infusions of \u03b2-lactam antibiotics in adults with sepsis or septic shock: a systematic review and meta-analysis","volume":"332","author":"Abdul-Aziz","year":"2024","journal-title":"JAMA"},{"key":"2026011413271342000_dkaf457-B50","doi-asserted-by":"publisher","first-page":"787","DOI":"10.1080\/17425255.2024.2385403","article-title":"Dose optimization of \u03b2-lactam antibiotics in children: from population pharmacokinetics to individualized therapy","volume":"20","author":"Ngougni Pokem","year":"2024","journal-title":"Expert Opin Drug Metab Toxicol"},{"key":"2026011413271342000_dkaf457-B51","doi-asserted-by":"publisher","first-page":"220","DOI":"10.1002\/phar.2505","article-title":"A guide to therapeutic drug monitoring of \u03b2-lactam antibiotics","volume":"41","author":"Fratoni","year":"2021","journal-title":"Pharmacotherapy"},{"key":"2026011413271342000_dkaf457-B52","doi-asserted-by":"publisher","first-page":"611","DOI":"10.1186\/s12879-022-07587-w","article-title":"Barriers and facilitators for therapeutic drug monitoring of beta-lactams and ciprofloxacin in the ICU: a nationwide cross-sectional study","volume":"22","author":"Ewoldt","year":"2022","journal-title":"BMC Infect Dis"},{"key":"2026011413271342000_dkaf457-B53","doi-asserted-by":"publisher","first-page":"624639","DOI":"10.3389\/fped.2021.624639","article-title":"Model-informed precision dosing of antibiotics in pediatric patients: a narrative review","volume":"9","author":"Abdulla","year":"2021","journal-title":"Front Pediatr"},{"key":"2026011413271342000_dkaf457-B54","doi-asserted-by":"publisher","first-page":"106931","DOI":"10.1016\/j.ijantimicag.2023.106931","article-title":"Which patients benefit from model-informed precision dosing of beta-lactam antibiotics and ciprofloxacin at the ICU?","volume":"62","author":"Ewoldt","year":"2023","journal-title":"Int J Antimicrob Agents"},{"key":"2026011413271342000_dkaf457-B55","doi-asserted-by":"publisher","first-page":"1059","DOI":"10.1093\/jac\/dkad046","article-title":"Plasma protein binding of ceftriaxone in critically ill patients: can we predict unbound fractions?","volume":"78","author":"Ewoldt","year":"2023","journal-title":"J Antimicrob Chemother"},{"key":"2026011413271342000_dkaf457-B56","doi-asserted-by":"publisher","first-page":"2148","DOI":"10.1093\/jac\/dkad196","article-title":"The neonatal and paediatric pharmacokinetics of antimicrobials study (NAPPA): investigating amoxicillin, benzylpenicillin, flucloxacillin and piperacillin pharmacokinetics from birth to adolescence","volume":"78","author":"Barker","year":"2023","journal-title":"J Antimicrob Chemother"}],"container-title":["Journal of Antimicrobial Chemotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/jac\/article-pdf\/81\/1\/dkaf457\/65849384\/dkaf457.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jac\/article-pdf\/81\/1\/dkaf457\/65849384\/dkaf457.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,14]],"date-time":"2026-01-14T18:27:18Z","timestamp":1768415238000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jac\/article\/doi\/10.1093\/jac\/dkaf457\/8377681"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,12]]},"references-count":56,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,1,6]]}},"URL":"https:\/\/doi.org\/10.1093\/jac\/dkaf457","relation":{},"ISSN":["0305-7453","1460-2091"],"issn-type":[{"value":"0305-7453","type":"print"},{"value":"1460-2091","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,1]]},"published":{"date-parts":[[2025,12,12]]},"article-number":"dkaf457"}}